Compare ASST & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASST | PHAT |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 998.7M | 894.0M |
| IPO Year | N/A | 2019 |
| Metric | ASST | PHAT |
|---|---|---|
| Price | $9.72 | $10.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $21.00 | $19.50 |
| AVG Volume (30 Days) | ★ 3.2M | 1.0M |
| Earning Date | 11-14-2025 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $92.15 |
| Revenue Next Year | N/A | $59.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $0.47 | $2.21 |
| 52 Week High | $13.40 | $18.31 |
| Indicator | ASST | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 58.99 | 42.36 |
| Support Level | $0.74 | $10.06 |
| Resistance Level | $10.09 | $11.19 |
| Average True Range (ATR) | 0.69 | 0.64 |
| MACD | -0.09 | 0.08 |
| Stochastic Oscillator | 56.12 | 38.83 |
Strive Inc is engaged in providing investment advisory, wealth management, and consulting services through its subsidiary. Its objectives is to (i) accumulate Bitcoin; (ii) increase Bitcoin-per-share; and (iii) outperform Bitcoin over the long run by deploying both beta Bitcoin treasury accumulation strategies and alpha investment strategies with the goal of beating Bitcoin's investment performance as the hurdle rate.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.